Historial de carrera de George Uy
Antiguos cargos conocidos de George Uy.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SORRENTO THERAPEUTICS, INC. | Corporate Officer/Principal | 09/09/2013 | 31/07/2015 |
| SPECTRUM PHARMACEUTICALS, INC. | Ventas & Marketing | 01/01/2007 | 01/06/2011 |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Ventas & Marketing | - | - |
Formación de George Uy.
| Cebu Institute of Medicine | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 4 |
| Filipinas | 2 |
Operativa
| Sales & Marketing | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
- Bolsa de valores
- Insiders
- George Uy
- Experiencia
